# A Study of Mealtime Insulin LY900014 in Participants With Type 2 Diabetes Using Continuous Glucose Monitoring (PRONTO-Time in Range)

> **NCT04605991** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 187 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** LY900014
- **DRUG:** Insulin Glargine

## Key facts

- **NCT ID:** NCT04605991
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-04
- **Primary completion:** 2022-02-04
- **Final completion:** 2022-02-04
- **Target enrollment:** 187 (ACTUAL)
- **Last updated:** 2023-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04605991

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04605991, "A Study of Mealtime Insulin LY900014 in Participants With Type 2 Diabetes Using Continuous Glucose Monitoring (PRONTO-Time in Range)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04605991. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*